The transition to recombinant endotoxin testing in the pharmaceutical industry is growing. Recombinant technologies offer technical advancements, better lot-to-lot reproducibility, and enhanced specificity to endotoxins.
This infographic offers practical guidance to support the transition to recombinant reagents, outlining key considerations for implementation and validation, and exploring how microfluidic solutions can help build a more sustainable, resilient, and robust endotoxin control strategy.